The South San Francisco company (NASDAQ: CYTK) lost $12.5 million a year earlier in the fourth quarter. Revenue rose slightly to $1.1 million from $1 million in the same quarter of 2009.
Cytokinetics lost $49.3 million in 2010, compared with a profit of $24.5 million in 2009, when $74.4 million in license revenue swelled its coffers.
Revenue in 2010 was $2.6 million, down from $81.5 million in 2009.
Those figures work out to a loss of 17 cents a share in the fourth quarter of 2010, down from a loss of 21 cents a share in the fourth quarter of 2009. But Cytokinetics had more shares outstanding -- about 5.2 million more -- in the most recent quarter, which made that per share loss figure smaller.
For 2010, Cytokinetics lost 77 cents a share, compared with a profit of 42 cents per diluted share in 2009.
The company guesses it will have from $2 million to $4 million in revenue in 2011.
Grant Heidrich and Michael Schmertzler resigned from the company’s board of directors and were replaced by Santo Costa and Wendell Wierenga.
Robert Blum is CEO of Cytokinetics.
Read more: Cytokinetics loses $11.6M in Q4 | San Francisco Business Times
